ENTBF News and Press, Entheon Biomedical Corp Com From 06/17/21

Vancouver, British Columbia--(Newsfile Corp. - June 17, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ( "Entheon" ), a biotechnology company focused on developing psychedelic medicines to treat addiction, and Silo Wellness Inc. (CSE: SILO) (OTC: SILFF) (FSE:3K70) ( "S...

Entheon Biomedical ([[ENTBF]] +2.8%) has entered into a definitive agreement to acquire personalized genetics company Lobo Genetics.Pursuant to the agreement, the company will issue an aggregate of 5M shares to the shareholders of Lobo.Under the deal, which is structured as a three-...

Genetic Screening Platform Technology and Data to Strengthen Entheon's Psychedelic-Assisted Protocols Vancouver, British Columbia--(Newsfile Corp. - June 16, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company ") is pleased to announce that th...

HaluGen Life Sciences' test evaluates an individual's overall sensitivity and risk profile associated with psychedelic-assisted therapy Vancouver, British Columbia--(Newsfile Corp. - June 10, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) ("Entheon" or the "Company"),...

Entheon Biomedical (ENTBF) has entered into a drug-supply agreement with Laboratorium Ofichem BV.Under the terms of the agreement, Ofichem will supply Entheon with GMP quality N,N-dimethyltryptamine drug substances ("DMT").Ofichem will provide GMP DMT product as well as the required analytica...

Vancouver, British Columbia--(Newsfile Corp. - May 18, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: 1XU1) (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, announced it has entered into a drug-supply a...

Launch of Psychedelics DNA Test Kit Phase 1 clinical trial for DMT progressing as planned Pre-clinical In Vivo work scheduled to start at Israeli CRO Strengthened expertise focused on driving initiatives forward Upgraded OTC Listing Financial Update Vancouver, British Columbia--(Newsf...

Vancouver, British Columbia--(Newsfile Corp. - May 11, 2021) - Entheon Biomedical Corp. (CSE: ENBI) today announced that, Timothy Ko, CEO of Entheon, will be attending the Q2 Virtual Investor Summit.   About Entheon Biomedical Corp. Entheon Biomedical is a drug development and ...

Vancouver, British Columbia--(Newsfile Corp. - May 5, 2021) - Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) (FSE: "1XU1") (" Entheon " or the " Company "), a biotechnology company focused on developing psychedelic medicines to treat addiction, is pleased to announce that it has been appr...

Toronto, Ontario--(Newsfile Corp. - March 30, 2021) - Microdose Psychedelic Insights ("Microdose"), the leader in B2B psychedelic intelligence, in partnership with The Conscious Fund , the most active VC fund in the psychedelic space, is pleased to present the next edition of Psychedelic ...